<DOC>
	<DOC>NCT01679834</DOC>
	<brief_summary>This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.</brief_summary>
	<brief_title>An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Diagnosis of chronic hepatitis C Patients receiving treatment with Pegasys and/or Copegus (ribavirin) and/or a protease inhibitor according to local label Contraindications against Pegasys or Copegus Not willing or unable to sign written informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>